Farrell Peter C
- SEC CIK
- 0001186102
In the past year, 8 open-market sale filings worth $5.01M and no purchases.
Current role at each company
- RMD Resmed IncDirectoras of Sep 4, 2026
- ARCT Arcturus Therapeutics Holdings Inc.Directoras of Jun 15, 2026
- EOLS Evolus, Inc.Directoras of Jan 31, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $5.01M
- 8 filings
- Net
- −$5.01M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Farrell Peter C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
RMD Resmed Inc
Director21 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2022 (view filing) | Oct 31 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −9.05K | $221.98 | −$2.01M | −4.7%183.1K after | |
| Feb 23, 2024 (view filing) | May 3, 2023-Feb 22, 2024 | 296 daysLate | Farrell Peter CDirector | SSaleResMed Common Stock | −23.5K | $211.84 | −$4.99M | −13.0%157.4K after | 2 lots |
| Sep 6, 2024 (view filing) | Sep 4 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $239.90 | −$479.8K | −2.2%87.2K after | 10b5-1 |
| Oct 2, 2024 (view filing) | Oct 2 | Same day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $237.20 | −$474.4K | −2.3%85.2K after | 10b5-1 |
| Nov 8, 2024 (view filing) | Nov 6 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $248.74 | −$497.5K | −2.3%83.2K after | 10b5-1 |
| Dec 5, 2024 (view filing) | Dec 4 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $245.65 | −$491.3K | −2.4%81.2K after | 10b5-1 |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $230.99 | −$462.0K | −2.5%79.2K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 5 | Same day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $242.11 | −$484.2K | −2.5%77.2K after | 10b5-1 |
| Mar 6, 2025 (view filing) | Mar 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $227.71 | −$455.4K | −2.6%75.2K after | 10b5-1 |
| Apr 4, 2025 (view filing) | Apr 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $219.74 | −$439.5K | −2.7%73.2K after | 10b5-1 |
EOLS Evolus, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 (view filing) | Sep 6 | Same day | Farrell Peter CDirector | PPurchase | +10.0K | $9.10 | +$91.0K | New position10.0K after |